Second Quarter 2026
Filed Aug 12, 2026Kura Oncology Reports SECOND Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q
KOMZIFTI commercialization showed sequential momentum, with $9.1 million in net product revenue, approximately 115 new patient starts, and more than 250 total prescriptions, while Kura reported a $68.3 million net loss and cash, cash equivalents and short-term investments of $519.0 million.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| KOMZIFTI net product revenueother | $9.1 million | 57% increase from 1Q 2026 | – |
| Collaboration revenueother | $11.8 million | – | – |
| Research and development expensesother | $61.9 million | – | – |
| Selling, general and administrative expensesother | $31.8 million | – | – |
| Net lossother | $68.3 million | – | – |
| Non-cash, share-based compensation expenseother | $8.2 million | – | – |
| Cash, cash equivalents and short-term investmentsother | $519.0 million | – | – |
| KOMZIFTI new patient startsother | Approximately 115 new patient starts (NPS) | 35% increase from 1Q 2026 | – |
| KOMZIFTI total prescriptionsother | More than 250 total prescriptions (TRx) in 2Q 2026 | 59% increase from 1Q 2026 | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| KOMZIFTI commercial launchApproximately 115 new patient starts, more than 250 total prescriptions including repeat prescriptions, broader adoption across academic and community treatment centers, and physician-directed use in combination with established standards of care. | $9.1 million in net product revenue | 57% increase from 1Q 2026 | – |
2026 through 2H 2027 outlook
- NoteKura expects multiple commercial and clinical catalysts over the next 12 to 18 months.
- NoteDeliver sustained quarter-over-quarter growth.
- NoteUpdated long-term KOMET-007 Phase 1b data in newly diagnosed, intensive chemotherapy-ineligible NPM1-m AML patients: 2H 2026.
- NoteInitial KOMET-007 Phase 1b data with 7+3 intensive chemotherapy and quizartinib in newly diagnosed NPM1-m/FLT3-ITD AML: 2H 2026.
- NoteInitial KOMET-008 data with gilteritinib in R/R NPM1-m/FLT3-m AML: 2H 2026.
- NoteExploratory KOMET-001 monotherapy analysis in MEIS1-associated AML subtypes: 2H 2026.
- NoteComplete enrollment in the randomized FIT-001 Phase 1b study in cabozantinib-naïve ccRCC: 1H 2027.
- NoteReport initial clinical data from the randomized FIT-001 Phase 1b study: 2H 2027.
- NoteInitiate a platform study of darlifarnib plus daraxonrasib in KRAS-mutant 2L+ PDAC: 1H 2027.
- NoteCurrent cash resources will be sufficient to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.
What drove it
- KOMZIFTI achieved a majority share of new patient starts in the R/R NPM1-m AML menin inhibitor class in its second full quarter on the market.
- EHA 2026 long-term KOMET-007 data for 600 mg ziftomenib plus intensive chemotherapy in 99 patients with newly diagnosed NPM1-m or KMT2A-r AML showed CRc rates of 96% and 90%, respectively, and 12-month OS rates of 94% and 71%, respectively.
- Updated KOMET-007 results in R/R NPM1-m AML reported an 87% ORR and 70% CRc rate in venetoclax-naïve patients. Median duration of CRc was 9.2 months, and median OS was not reached after 10.7 months of follow-up.
- Darlifarnib plus adagrasib data showed tumor shrinkage in 77% of response-evaluable patients and confirmed ORRs of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer.
- Darlifarnib plus cabozantinib in cabozantinib-naïve clear cell renal cell carcinoma showed ORRs of up to 50% across dose levels and an mPFS of 13 months.
- In cabozantinib-exposed clear cell renal cell carcinoma, darlifarnib plus cabozantinib achieved a 44% ORR, 94% disease control rate, and tumor shrinkage in 75% of patients.
Concerns
- Collaboration revenue was $11.8 million, compared to $15.3 million for 2Q 2025.
- SG&A expenses were $31.8 million, compared to $25.2 million for 2Q 2025.
- Net loss was $68.3 million, compared to $66.1 million for 2Q 2025.
- Cash, cash equivalents and short-term investments were $519.0 million as of June 30, 2026, compared to $667.2 million as of December 31, 2025.
- Clinical and commercial milestones remain prospective, including data presentations anticipated in 2H 2026 and darlifarnib study milestones in 1H 2027 and 2H 2027.
What to watch
- Sustained quarter-over-quarter growth in KOMZIFTI net product revenue, new patient starts, total prescriptions, repeat prescribing, and physician adoption.
- Updated and initial ziftomenib clinical data anticipated in 2H 2026 from KOMET-007, KOMET-008, and KOMET-001.
- Progress of enrollment across KOMET-017 frontline registrational studies, KOMET-008, and the KOMET-007 cohort evaluating ziftomenib plus quizartinib and intensive chemotherapy.
- Completion of FIT-001 Phase 1b enrollment in 1H 2027 and initial clinical data in 2H 2027.
- The anticipated $180 million in collaboration payments from Kyowa Kirin and the stated cash runway through anticipated 2028 Phase 3 KOMET-017 topline results.
Balance sheet and cash flow
- $519.0 million in cash, cash equivalents and short-term investments as of June 30, 2026, compared to $667.2 million as of December 31, 2025.
- $180 million in anticipated collaboration payments from Kyowa Kirin.
- The Company believes its current cash resources will be sufficient to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.
Analysis
Kura reported early commercial momentum for KOMZIFTI in its second full quarter of launch. Net product revenue was $9.1 million, a 57% increase from 1Q 2026. Approximately 115 new patient starts rose 35% from 1Q 2026, while more than 250 total prescriptions, including repeat prescriptions, rose 59% from 1Q 2026. The company also said KOMZIFTI achieved a majority share of new patient starts in the R/R NPM1-m AML menin inhibitor class.
The revenue mix included $11.8 million of collaboration revenue, compared to $15.3 million for 2Q 2025. Kura did not report total revenue in the provided release. Research and development expenses were $61.9 million, compared to $62.8 million for 2Q 2025, while SG&A expenses increased to $31.8 million from $25.2 million. Net loss was $68.3 million, compared to $66.1 million for 2Q 2025, and included $8.2 million in non-cash, share-based compensation expense.
Clinical execution remains centered on expanding ziftomenib across AML settings and developing darlifarnib combinations in solid tumors. Long-term KOMET-007 data and updated data in R/R NPM1-m AML were cited as support for ongoing frontline and combination programs. The company also highlighted darlifarnib activity across KRAS G12C-mutated tumors and clear cell renal cell carcinoma, with the randomized FIT-001 Phase 1b study continuing enrollment.
Liquidity was $519.0 million in cash, cash equivalents and short-term investments as of June 30, 2026, compared to $667.2 million as of December 31, 2025. Kura additionally cited $180 million in anticipated collaboration payments from Kyowa Kirin and stated that current cash resources should fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028. The release provided no financial revenue, margin, expense, or tax-rate guidance, leaving commercial trajectory and upcoming 2H 2026 clinical updates as the principal disclosed near-term markers.
Management, verbatim
In only its second full quarter of launch, KOMZIFTI established early leadership in relapsed or refractory NPM1 -mutant AML, achieving a majority share of new patient starts in the menin inhibitor class.
Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology
Not in the filing
stated, not guessed- Total revenue.
- Gross profit and gross margin.
- Operating income or operating loss.
- GAAP and non-GAAP diluted EPS.
- Non-GAAP revenue, expenses, operating income or loss, net income or loss, and EPS.
- Prior-quarter collaboration revenue, R&D expenses, SG&A expenses, net loss, and share-based compensation expense.
- Year-over-year percentage changes for collaboration revenue, R&D expenses, SG&A expenses, net loss, share-based compensation expense, and cash.
- Operating cash flow and free cash flow.
- Debt.
- Share repurchases, dividends, and other capital returns.
- Financial guidance for revenue, gross margin, operating expenses, and tax rate.
- Prior-quarter outlook for comparison.
- Reportable operating segments and segment revenue beyond KOMZIFTI net product revenue.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.